Melissa Klutts
Family · Council Bluffs, IANPI 1215445077
Payments from drug & device makers
Across 140 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$474
- Novo Nordisk$249
- AstraZeneca$212
- AbbVie$122
- Mylan Specialty L.p.$109
- Otsuka America Pharmaceutical, Inc.$108
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,37399%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,396 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 104 | $78,197 |
| MounjaroTirzepatide | 67 | $75,718 |
| TrulicityDulaglutide | 32 | $39,617 |
| OzempicSemaglutide | 30 | $37,161 |
| JardianceEmpagliflozin | 42 | $32,660 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,900 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,418 |
| FarxigaDapagliflozin Propanediol | 16 | $9,951 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,405 |
| BelsomraSuvorexant | 32 | $5,755 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,310 |
| Rosuvastatin Calcium | 133 | $2,355 |
| Memantine Hcl | 28 | $1,732 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,269 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $474 | $115,33499 claims |
| PfizerEliquis | $91 | $78,197104 claims |
| Novo NordiskOzempic | $249 | $37,16130 claims |
| Boehringer IngelheimJardiance | $20 | $32,66042 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $212 | $22,85237 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $53 | $17,72824 claims |
| MerckBelsomra | $14 | $5,75532 claims |
| AbbVieSynthroid | $122 | $56619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.
Other family in Council Bluffs
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.